Establishing a screening program for endometriosis and polyendocrine metabolic ovarian syndrome

Summary#

Introduction 295-A would amend the New York City Administrative Code provision on the Department of Health and Mental Hygiene’s sexual and reproductive health work. It would require the Department to establish a screening program for endometriosis and “polyendocrine metabolic ovarian syndrome”—the term used in the bill’s text. Its stated purpose is to establish that program; the bill does not say what results it would achieve.

  • The Department would have to screen patients who display or have displayed symptoms of the two named conditions.
  • The bill adds both conditions to the topics for which the Department must provide outreach, education, and support.
  • The Department must make referrals for services related to those conditions when it determines referrals are appropriate.
  • The prime sponsor is Council Member Farah N. Louis. The amended bill was laid over in the Committee on Women and Gender Equity on September 30, 2026. It has not become law.

What it means for you#

  • Patients with symptoms: The bill describes them as the group to be screened. It does not set out how to access screening or guarantee a particular test or follow-up service.
  • People seeking information or referrals: The Department would have to include the two conditions in its outreach, education, and support. Referrals would depend on the Department determining they are appropriate.
  • Department of Health and Mental Hygiene: It would have to establish and operate the screening program and add the conditions to its outreach and referral work.
  • Current law: The text amends an existing Administrative Code provision that already covers sexual and reproductive health services, research, outreach, and referrals. The supplied materials do not include the full current provision, so the exact differences from current law cannot be independently verified.

Money#

No cost information is in the available material.

  • The bill assigns new duties to the Department but gives no staffing or spending estimate and makes no specific appropriation.

What is unclear#

  • The bill does not define “polyendocrine metabolic ovarian syndrome.” The Council’s summary uses “polycystic ovarian syndrome” instead; the bill text controls, but the materials do not explain the difference.
  • It does not specify screening methods, where screening would happen, who would provide it, or how patients would enter the program.
  • It does not set out follow-up care, timelines, oversight, or reporting requirements.
  • The bill takes effect 120 days after it becomes law, but passage is uncertain while it remains laid over in committee.

Case for#

  • A possible argument for the bill is that screening people who have symptoms could help identify the two conditions, while outreach and education could make information about them more available.
  • The bill adds these conditions to an existing city health-services provision, rather than creating a new independent agency.

Case against#

  • One concern is that the bill requires a screening program but leaves its methods, access rules, and follow-up arrangements unspecified.
  • It is unclear what resources the Department would need to carry out the new duties, since the bill gives no cost or staffing estimate.
  • The difference between the condition named in the bill and the one named in the Council’s summary could create uncertainty about what the program must cover.